By
Latest Stories
Don’t miss our hot and upcoming stories
How Unlearn AI Is Increasing the Efficiency of Phase 2 Clinical Trials with AI-Powered TwinRCT
December 11, 2024 Enhanced TwinRCT™ 3.0 Unlearn® has introduced an upgraded version of its AI-driven…
Relation Therapeutics, NVIDIA-Backed AI-Biotech, and GSK Announce Strategic Collaborations to Advance Therapies for Fibrotic Diseases and Osteoarthritis
London, UK – December 10, 2024 Relation, a leader in computational and experimental drug discovery,…
Recursion Reports Promising Interim Data for AI-Designed CDK7 Inhibitor in Ovarian Cancer
Salt Lake City – December 9, 2024 Recursion (Nasdaq: RXRX), a leader in AI-powered drug…
Recursion Doses First Patient in Phase 1/2 Trial of REC-1245 for Biomarker-Enriched Solid Tumors and Lymphoma
Recursion (NASDAQ: RXRX), a cutting-edge clinical-stage TechBio company, has announced the successful dosing of the…